Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659916 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
A Phase 3 study, sponsored by Albireo, an Ipsen Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT03659916 is a Phase 3 study that has completed, run by Albireo, an Ipsen Company. The registered enrollment target is 116 participants.
The verdict
NCT03659916, a Phase 3 study, has completed, sponsored by Albireo, an Ipsen Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
Open Label Extension Study to evaluate long term safety and persistence of effect of A4250 in children with PFIC.
Interventions
- DRUG A4250 (odevixibat)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03659916
The ClinicalTrials.gov registry entry for NCT03659916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albireo, an Ipsen Company, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A4250 (odevixibat) is the first listed.
NCT03659916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03659916 about?
NCT03659916 is a clinical study titled "Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC". Open Label Extension Study to evaluate long term safety and persistence of effect of A4250 in children with PFIC.
What is the current status of trial NCT03659916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2018-09-28. Estimated completion is 2025-12-02.
What interventions are being tested in trial NCT03659916?
The interventions under investigation include: A4250 (odevixibat) (DRUG).
Who is sponsoring clinical trial NCT03659916?
This trial is sponsored by Albireo, an Ipsen Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.